Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM201 Combined with Radiotherapy in Advanced Solid Tumors
NCT06368960Phase 1Recruiting
- Sponsor
- InnoBM Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BM201 in solid tumor (advanced stage) (2 arms), sponsored by InnoBM Pharmaceuticals. Primary endpoints: Dose Limiting Toxicity at 14 days, Maximum Tolerated Dose at 14 days and 2 more. Started Nov 2022; status: recruiting.
02
Drugs
BM201
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06368960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368960.